CompletedPhase 3

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

United States, Australia71 participantsStarted 2013-03-31

Plain-language summary

The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Severe hemophilia (defined as \< 1% factor activity level) * Infection with the hepatitis C virus (HCV) with underlying hemophilia * Males 18 years of age and above * Have not been previously treated with an interferon Exclusion Criteria: * Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV) * Chronic liver disease caused by any disease other than chronic HCV infection * Presence of Bethesda inhibitor * Current evidence of or history of portal hypertension

What they're measuring

Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12

Timeframe: Follow-up Week 12

Trial details

NCT IDNCT01741545

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-01-31

Results submitted2019-03-22

View on ClinicalTrials.gov More Hepatitis C Virus trials